Insys Therapeutics, Inc. (NASDAQ:INSY) has enrolled the first patient in a Phase II clinical trial for the treatment of cocaine dependence using its pharmaceutical cannabidiol (CBD) product candidate, the company said on Thursday.
CBD is one of at least 60 active cannabinoids identified in cannabis and is considered by many to have a wider scope of medical applications than does tetrahydrocannabinol. Insys’ pharmaceutical CBD is over 99.5% pure cannabidiol.
The study is being conducted by Dr. Didier Jutras-Aswad, MD, at the University of Montreal Hospital Research Center (CRCHUM) and is supported by the Canadian Institutes of Health Research (CIHR) and by Insys.
“We are pleased to have begun enrollment in this important trial to treat cocaine dependence, a disease afflicting people in every part of society,” said Santosh Vetticaden, MD, PhD, Senior Vice President and Chief Medical Officer of Insys Therapeutics.
“If successful, we anticipate